265 related articles for article (PubMed ID: 33790563)
1. Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.
Simonetti O; Rizzetto G; Molinelli E; Cirioni O; Offidani A
Ther Clin Risk Manag; 2021; 17():223-232. PubMed ID: 33790563
[TBL] [Abstract][Full Text] [Related]
2. Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation.
Righi E; Visentin A; Meroi M; Carrara E; Tacconelli E
Expert Opin Drug Saf; 2022 Sep; 21(9):1171-1181. PubMed ID: 36093622
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
[TBL] [Abstract][Full Text] [Related]
4. Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center.
Brescini L; Della Martera F; Morroni G; Mazzanti S; Di Pietrantonio M; Mantini P; Candelaresi B; Pallotta F; Olivieri S; Iencinella V; Castelletti S; Cocci E; Polo RG; Veccia S; Cirioni O; Tavio M; Giacometti A
Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572711
[TBL] [Abstract][Full Text] [Related]
5. Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients: a case series.
Garbo V; Condemi A; Albano C; Polara VF; Parrino R; Macaluso A; Venuti L; Colomba C
Infez Med; 2024; 32(2):231-240. PubMed ID: 38827834
[TBL] [Abstract][Full Text] [Related]
6. The current and future off-label uses of dalbavancin: a narrative review.
De Vito A; Fiore V; Colpani A; Zauli B; Fanelli C; Tiseo G; Occhineri S; Babudieri S; Falcone M; Madeddu G
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1222-1238. PubMed ID: 36808371
[TBL] [Abstract][Full Text] [Related]
7. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Ramdeen S; Boucher HW
Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Leuthner KD; Buechler KA; Kogan D; Saguros A; Lee HS
Ther Clin Risk Manag; 2016; 12():931-40. PubMed ID: 27354809
[TBL] [Abstract][Full Text] [Related]
9. The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections.
Giorgobiani M; Burroughs MH; Antadze T; Carrothers TJ; Riccobene TA; Patel R; Lin T; Stefanova P
Pediatr Infect Dis J; 2023 Mar; 42(3):199-205. PubMed ID: 36476623
[TBL] [Abstract][Full Text] [Related]
10. The role of long-acting antibiotics in the clinical practice: a narrative review.
Micheli G; Chiuchiarelli M; Taccari F; Fantoni M
Infez Med; 2023; 31(4):449-465. PubMed ID: 38075413
[TBL] [Abstract][Full Text] [Related]
11. Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials.
Gonzalez PL; Rappo U; Mas Casullo V; Akinapelli K; McGregor JS; Nelson J; Nowak M; Puttagunta S; Dunne MW
Infect Dis Ther; 2021 Mar; 10(1):471-481. PubMed ID: 33515414
[TBL] [Abstract][Full Text] [Related]
12. Global trends of dalbavancin: A bibliometric analysis.
Monteagudo-Martínez N; Solís García Del Pozo J; Ikuta I; Galindo MF; Jordán J
J Clin Pharm Ther; 2022 Sep; 47(9):1299-1311. PubMed ID: 35735062
[TBL] [Abstract][Full Text] [Related]
13. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
14. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
Dunne MW; Talbot GH; Boucher HW; Wilcox M; Puttagunta S
Drug Saf; 2016 Feb; 39(2):147-57. PubMed ID: 26715497
[TBL] [Abstract][Full Text] [Related]
15. Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Garnock-Jones KP
Drugs; 2017 Jan; 77(1):75-83. PubMed ID: 27988870
[TBL] [Abstract][Full Text] [Related]
16. A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.
Dimopoulou D; Mantadakis E; Koutserimpas C; Samonis G
Antibiotics (Basel); 2023 Sep; 12(10):. PubMed ID: 37887193
[TBL] [Abstract][Full Text] [Related]
17. Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.
Smith JR; Roberts KD; Rybak MJ
Infect Dis Ther; 2015 Sep; 4(3):245-58. PubMed ID: 26341488
[TBL] [Abstract][Full Text] [Related]
18. A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice.
Hanses F; Dolff S; Trauth J; Seimetz M; Hagel S
Antibiotics (Basel); 2022 Apr; 11(5):. PubMed ID: 35625206
[TBL] [Abstract][Full Text] [Related]
19. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
Soriano A; Rossolini GM; Pea F
Expert Rev Anti Infect Ther; 2020 May; 18(5):415-422. PubMed ID: 32223465
[No Abstract] [Full Text] [Related]
20. Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection in Patients With Obesity or Diabetes: A Subgroup Analysis of Pooled Phase 3 Clinical Trials.
Riccobene T; Lock J; Lyles RD; Georgiades B; Nowak M; Gonzalez PL; Park J; Rappo U
Open Forum Infect Dis; 2023 Jun; 10(6):ofad256. PubMed ID: 37305839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
